Flavopiridol in Treating Patients With Recurrent or Persistent Endometrial Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed primary endometrial carcinoma
• * Recurrent or persistent disease
• * Refractory to curative therapy or established treatment
• Previously treated with only 1 prior cytotoxic chemotherapy regimen (either single agent or combination therapy) for endometrial carcinoma
• * Initial treatment may include high-dose, consolidation, or extended therapy administered after surgical or non-surgical assessment
• At least 1 unidimensionally measurable lesion
• * At least 20 mm by conventional techniques OR
• * At least 10 mm by spiral CT scan
• * At least 1 target lesion outside previously irradiated field
• Ineligible for higher priority Gynecologic Oncology Group (GOG) protocol, defined as any active GOG phase III protocol for the same patient population
• PATIENT CHARACTERISTICS:
• Age:
• Any age
• Performance status:
• GOG 0-2
• Life expectancy:
• Not specified
• Hematopoietic:
• Absolute neutrophil count at least 1,500/mm\^3
• Platelet count at least 100,000/mm\^3
• Hepatic:
• Bilirubin no greater than 1.5 times upper limit of normal (ULN)
• SGOT no greater than 2.5 times ULN
• Alkaline phosphatase no greater than 2.5 times ULN
• PT/PTT normal
• Renal:
• Creatinine no greater than 1.5 times ULN
• Cardiovascular:
• No prior thromboembolic events or thrombophlebitis
• No prior recent myocardial infarction
• No prior angina
• No prior cerebrovascular accident
• No prior transient ischemic attacks
• Other:
• No other invasive malignancy within the past 5 years except nonmelanoma skin cancer
• No grade 2 or greater sensory or motor neuropathy
• No active infection requiring antibiotics
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• At least 3 weeks since prior biologic or immunologic agents for endometrial carcinoma
• Chemotherapy:
• See Disease Characteristics
• At least 3 weeks since prior chemotherapy for endometrial carcinoma and recovered
• Endocrine therapy:
• At least 1 week since prior hormonal therapy for endometrial carcinoma
• Concurrent hormone replacement therapy allowed
• Radiotherapy:
• See Disease Characteristics
• At least 3 weeks since prior radiotherapy for endometrial carcinoma and recovered
• Surgery:
• At least 3 weeks since prior surgery for endometrial carcinoma and recovered
• At least 6 months since prior re-vascularization procedures (e.g., coronary artery bypass graft, carotid endarterectomy or bypass, or angioplasty with or without stents)
• Other:
• At least 3 weeks since other prior therapy for endometrial carcinoma
• At least 6 months since prior thrombolytic procedures
• No prior cyclin-dependent kinase inhibitors
• No prior anticancer therapy that would preclude study
• No concurrent amifostine or other protective reagents